Journal
CEPHALALGIA
Volume 28, Issue 7, Pages 683-688Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1111/j.1468-2982.2008.01600.x
Keywords
migraine; adverse events; assessment; reporting
Categories
Ask authors/readers for more resources
Tolerability of a drug should be regarded as important as its efficacy. In all four phases of drug development evaluation of adverse events is important. Recommendations for assessment of adverse events in acute and prophylactic clinical drug trials in migraine are given. Tolerability may be indirectly assessed using measures of general well-being and eight such tools are presented. Finally, recommendations for reporting of adverse events are given.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available